Source comparison
GHRP-6 vs GHRP-2, Ipamorelin, and Hexarelin: Receptor Selectivity and Side-Effect Profiles
GRHP-6 is one of several synthetic growth hormone secretagogues used in peptide research, and understanding how it differs from structurally similar compounds. GHRP-2, ipamorelin, and hexarelin. Is essential for protocol design. All four peptides bind to GHS-R
This comparison does not assign a generated winner or score.
- GRHP-6 is one of several synthetic growth hormone secretagogues used in peptide research, and understanding how it differs from structurally similar compounds. GHRP-2, ipamorelin, and hexarelin. Is essential for protocol design. All four peptides bind to GHS-R1a receptors and stimulate growth hormone release, but they differ significantly in receptor selectivity, off-target activity, and side-effect profiles.
- GHRP-6
- High
- Moderate to Strong. Increases food intake 30–50% in rodent models at doses >150 mcg/kg
- Minimal. Does not significantly elevate cortisol or prolactin at standard doses
- Low. Sustained use does not reduce GH response over 4–6 weeks
- 100–300 mcg/kg subcutaneous
- GHRP-2
- Mild. Smaller appetite effect than GHRP-6, increases intake 10–20% at equivalent doses
- Minimal
- Low
- Ipamorelin
- Moderate
- None. Does not increase food intake at any dose tested in rodent models
- None. Highly selective, no cortisol or prolactin elevation
- Very Low. No desensitization observed in 12-week rodent studies
- 200–500 mcg/kg subcutaneous
- Hexarelin
- Very High
- Mild
- Moderate. Dose-dependent cortisol and prolactin elevation at doses >200 mcg/kg
- High. GH response diminishes significantly after 2–3 weeks of daily use
- 100–200 mcg/kg subcutaneous
- GRHP-6's defining characteristic is its strong appetite-stimulating effect, mediated through GHS-R1a activation in the arcuate nucleus of the hypothalamus. This makes GHRP-6 particularly useful in research models studying cachexia (muscle wasting), anorexia, or metabolic recovery after caloric restriction. Contexts where increased food intake is a desired outcome. In contrast, ipamorelin produces equivalent growth hormone release without affecting appetite, making it the preferred secretagogue in studies where food intake must remain constant.
- Hexarelin, while producing the highest growth hormone peaks of the four peptides, also activates non-GHS-R1a pathways that elevate cortisol and prolactin. This off-target activity complicates interpretation in metabolic studies and introduces confounding endocrine variables. Additionally, hexarelin exhibits rapid desensitization: daily administration for more than two weeks in rodent models produces progressively smaller growth hormone responses, likely due to GHS-R1a receptor downregulation or internalization. GHRP-6 and GHRP-2 do not show this pattern. Growth hormone response remains stable across 4–6 weeks of daily dosing.
- Ipamorelin's selectivity comes at a cost: it has lower receptor affinity than GHRP-6 or hexarelin, requiring higher doses to produce equivalent growth hormone peaks. In head-to-head comparisons, 300 mcg/kg ipamorelin produces growth hormone elevation roughly equivalent to 150 mcg/kg GHRP-6. The trade-off is fewer side effects versus higher compound consumption per study.
- Our experience supplying secretagogues to metabolic research labs shows a clear protocol pattern: GHRP-6 is chosen when appetite modulation is part of the research question, Ipamorelin is chosen when growth hormone stimulation must occur without confounding food intake changes, and Hexarelin is used only in short-term acute studies where maximal growth hormone response is needed and cortisol elevation is not a disqualifying factor.